Novavax gained a US Department of Defense contract for its vaccine candidate recently, and is confident its nanoparticle approach provides a good alternative to other technologies.
Reports that the final shortlist of coronavirus vaccine candidates in Operation Warp Speed has been decided are premature, says US company Novavax Inc.–with a strong suggestion from the biotech’s R&D chief that his company is still very much in the running.
Operation Warp Speed, President Trump’s special project to accelerate the delivery of a coronavirus vaccine by late 2020, was launched on 15 May, with ex-industry vaccines veteran Moncef Slaoui chosen...
Updated Phase II results from petosemtamab have impressed ahead of ASCO, outshining Keytruda monotherapy and its bispecific rival from Bicara.
Zydus expects strong mirabegron sales in FY26 amid US litigation even as it builds a growth pillar in vaccines with a world-first, Gates Foundation-aided dual shigella-typhoid vaccine under development and others on the WHO prequalified list
The royalty revenue stream acquirer has around 40 products in its portfolio and expects to generate roughly $3bn this year. Head of R&D and investments Marshall Urist talked about the investment strategy at the RBC Healthcare Conference.
